Clinical Trial Search

Primary: TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) — 52; 28; 49; 21 events

Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events

Primary: Change From Baseline in Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Total Score at Week 52 — 5.58; 5.54 score on a scale — p==0.961

Primary: Striatum Brain Region: Change From Baseline in Microglia Activation Via Positron Emission Tomography(PET) — -0.23; 0.12; -0.35 ml/cc — p=0.13

Primary: Change From Baseline in the Modified UMSARS Score at Week 48 — 5.20; 4.85 units on a scale — p=0.4656

Primary: Change From Baseline to Week 48/Termination Visit in the Total Unified Multiple System Atrophy Rating Scale (UMSARS Part I and II) — 7.2; 7.8 units on a scale — p=0.6984

Primary: Change in UMSARS Score (Parts I+II) From Baseline — 6.1; 13.3 score on a scale

Primary: Change of Score in Motor Examination (ME) of the Unified MSA Rating Scale (UMSARS-ME) From V1 to V7. — 5.66; 6.60 score on a scale — p=0.51

Primary: Percent Change From Baseline to Post Treatment on the Scale for the Assessment and Rating of Ataxia (SARA) — -25.9; -27.8 percentage change — p=0.29

Primary: Sensitivity of mPDia for the Diagnosis of Neurodegenerative Parkinsonism — 94.30 percentage

Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)

Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale

Primary: Scale for the Assessment and Rating of Ataxia(SARA) — 11.5; 9 score on a scale

Primary: Change in Frontal Midline Theta EEG Power After Brain Stimulation — 1.03; 0.44; 1.01 microvolts^2/Hz — p=0.08

Primary: Change in Verbal Fluency FAS (F, A or S Words) Total Score — 38.8; 41.0; 32.8; 30.8 Words

Primary: Muscle Weakness — 2; 3 Participants

Primary: Change in Sensitivity of QSM MR Imaging From Baseline MR Imaging to 24 Month MR Imaging — 379.5896; 314.1832; 561.1894; 288.1832 ppb — p=0.66

Primary: Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication. — -3.57; 1.85 Scores on a scale…

Primary: Correlation Coefficient Between UPDRS III Score and Independent Components Analysis Network Strength in Left Parietal Cortex. — 0.5869 unitless

Primary: Efficacy of Coenzyme Q10 (Unified Parkinson's Disease Rating Scale [UPDRS] AND Progressive Supranuclear Palsy Rating Scale [PSPRS]) — 5.9; 11.8; 11.5; 12.8 units on a…

Primary: Expanded Disability Status Scale (EDSS) Improvement — 3.4; 3.3; 2.5; 3.7 units on a scale

Primary: Demonstrate the Presence of Alpha-Synuclein Inclusions in the Skin of Parkinson's Disease and Compare With an Atypical Parkinsonism Group and With a Healthy Control…

Primary: Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) — -1.20; -0.94 units on a scale — p=0.07

Primary: Change in Patient Quality of Life as Measured by the EuroQol 5-D (EQ-5D) Scale Between Baseline (Visit 1) and 1 Year (Visit 4) — 1; 0.5; 0.5; 0 units on a scale — p=0.59

Primary: Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I (Mentation, Behaviour and Mood) — 2; 2 Points on a scale

Primary: Distribution Volume Ratio — 2.65; 2.70; 2.96; 2.74 Distribution volume ratios — p=0.05

Primary: ALS Functional Rating Scale-Revised (ALSFRS-R) — -1.00; -1.26 score on a scale

Primary: Sensitivity Analysis of the Blinded Independent Read of DaTSCAN™ SPECT Images — 0.851; 0.865; 0.919 ratio

Primary: L-DOPA Insensitivity — 5 Participants — p=0.00468

Primary: AChE PET Neuroimaging — 0.0238; 0.0226 1/min — p=0.0009